Barclays’s Tonix Pharmaceuticals TNXP Stock Holding History

Barclays’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$102K	Buy	10,472 +3,126	+43%	+$36.9K	﹤0.01%	4297
2026 Q2	$93.7K	Buy	7,346 +797	+12%	+$10.3K	﹤0.01%	4063
2026 Q1	$90K	Sell	6,549 -15,682	-71%	-$241K	﹤0.01%	4072
2025 Q4	$347K	Buy	22,231 +9,765	+78%	+$180K	﹤0.01%	4056
2025 Q3	$301K	Sell	12,466 -833	-6%	-$30.9K	﹤0.01%	4098
2025 Q2	$478K	Buy	+13,299	New	+$348K	﹤0.01%	3781
2018 Q2	–	Hold	0	–	–	–	7281
2018 Q1	–	Hold	0	–	–	–	7330
2017 Q2	–	Hold	0	–	–	–	6928
2017 Q1	–	Hold	0	–	–	–	6975
2013 Q4	–	Hold	0	–	-$2K	–	7680
2013 Q3	–	Hold	0	–	–	–	7207

Other funds holding TNXP

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Legato Capital Management San Francisco, California $1.11B AUM 60.78% 1-Year Est. Return

IEQ Capital Foster City, California $23.5B AUM 29.01% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

Barclays's TNXP Position: Q3 2026 in Review

Barclays increased its Tonix Pharmaceuticals (TNXP) stake by 43% in Q3 2026, buying an estimated $36.9K and bringing the position to 10,472 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #4297.

Barclays first reported a position in TNXP in Q2 2025 and has held it in 6 quarters since. The position peaked at $478K in Q2 2025. 50 funds tracked by Wall St. Rank hold TNXP as of Q3 2026.

Barclays held 10,472 shares of Tonix Pharmaceuticals worth $102K as of Q3 2026.
Barclays bought 3,126 Tonix Pharmaceuticals shares in Q3 2026, an estimated $36.9K.
Tonix Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4297 holding.
Barclays first reported a position in Tonix Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
Barclays's Tonix Pharmaceuticals position peaked at $478K in Q2 2025.
50 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.